A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
About the trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis.
Planned enrolment of 274 participants in 74 locations.
How DCR - CIU supports the trial
DCR - CIU is involved in multiple aspects of the trial conduct: the planning, coordination and conduct of the study visits; collection, processing, storage and shipping of biological samples, subcutaneous IMP administration and accountability, maintenance of the Investigator Site File, and data entry
Principal Investigator
Prof. Dr. med Dagmar Simon, Universitätsklinik für Dermatologie
Sponsor
Galderma R&D